Understanding LIGR
LIGR is a short synthetic peptide that researchers use as a research tool to study joint pain and cartilage damage. Think of it as a key designed to unlock specific receptors in your joints called PAR-2. Scientists are interested in this because understanding how PAR-2 works might eventually lead to better treatments for osteoarthritis pain.
Here's what happens when LIGR gets into your joint tissue: it activates those PAR-2 receptors, kind of like flipping a switch. When this switch flips in your cartilage cells, they start producing inflammatory chemicals — basically alarm signals that tell your body something's wrong. These chemicals contribute to cartilage breaking down and trigger pain. But LIGR also activates PAR-2 on your pain-sensing nerve endings in the joint. When those nerves get activated, they become hypersensitive, amplifying pain signals sent to your brain. It's like turning up the volume on your joint's pain alarm system.
Right now, researchers use LIGR primarily to understand exactly how this PAR-2 system contributes to joint problems. By mapping out this mechanism, scientists are working toward developing drugs that block PAR-2 instead of activating it — essentially turning down that pain amplifier for people suffering from osteoarthritis.
Dosage Information
Typical Dose
Research compound — used in preclinical joint biology studies
Frequency
N/A
Administration
Research compound
Half-Life
varies hours
estimatedNotes
LIGR itself is a research tool peptide used to study PAR-2 biology. Therapeutic interest is in PAR-2 antagonists for OA pain. This entry documents its research significance.
Why this matters
Research compound; limited pharmacokinetic data available.
Where does Leu-Ile-Gly-Arg-Lys sit?
See how this peptide compares across all 150 peptides in our database.
Evidence Score
0.07
Potential Side Effects
Leu-Ile-Gly-Arg-Lys discussions
Quick Facts
- Administration
- Research compound
- Typical Dose
- Research compound — used in preclinical joint biology studies
- Frequency
- N/A
- References
- 0 curated + 0 from PubMed
- Evidence Score
- 0.1 / 100
Frequently Asked Questions about Leu-Ile-Gly-Arg-Lys
What is Leu-Ile-Gly-Arg-Lys?
LIGR (Leu-Ile-Gly-Arg) is a synthetic peptide activator of protease-activated receptor 2 (PAR-2) that has been studied for its roles in joint pain sensitization and cartilage biology. PAR-2 is expressed throughout joint tissue including chondrocytes synoviocytes and sensory neurons and plays important roles in joint inflammation and pain transmission. Understanding LIGR and PAR-2 signaling has contributed to the development of PAR-2 antagonist strategies for osteoarthritis pain management.
How does Leu-Ile-Gly-Arg-Lys work?
LIGR activates PAR-2 receptors in joint tissue by mimicking the tethered ligand that is exposed when serine proteases cleave the PAR-2 extracellular domain. PAR-2 activation in chondrocytes stimulates the production of inflammatory mediators including prostaglandins and cytokines that contribute to cartilage degradation and joint pain. In sensory neurons innervating the joint PAR-2 activation sensitizes nociceptors increasing pain sensitivity — a mechanism called peripheral sensitization that amplifies joint pain in osteoarthritis. As a research tool LIGR has been valuable for studying PAR-2's role in joint pathology and identifying PAR-2 antagonism as a potential therapeutic target for OA pain. PAR-2 antagonist peptides derived from understanding LIGR pharmacology are in early development.
What is the recommended dosage for Leu-Ile-Gly-Arg-Lys?
The typical dose is Research compound — used in preclinical joint biology studies. N/A. Administration: Research compound. LIGR itself is a research tool peptide used to study PAR-2 biology. Therapeutic interest is in PAR-2 antagonists for OA pain. This entry documents its research significance.
What are the side effects of Leu-Ile-Gly-Arg-Lys?
Research compound — not for therapeutic use. PAR-2 activation increases joint inflammation in research models
Questions reflect common community inquiries. This is not medical advice.